- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01031420
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective To assess the rate of complete response (pT0) at cystectomy or ureterectomy following preoperative dose dense MVAC (DD-MVAC) in patients with muscle invasive urothelial carcinoma of the bladder or high grade upper tract urothelial carcinoma.
Secondary Objectives To assess the toxicity profile of DD-MVAC when given in the neoadjuvant setting: To define the number of patients who complete all three cycles of treatment without dose reduction, and to compare incidence of toxicity to the historical standard described by Grossman et al. To assess the 5 year overall and relapse free survival in patients who receive neoadjuvant DD-MVAC. To compare complete response rates between the following subgroups of study patients: Among bladder patients: Clinical N0 versus N1 (Appendix B) Among bladder patients: T2 stage without high risk features versus T2 with high risk features plus those with > T2 stage.
Three 14 day cycles of:
Methotrexate 30 mg/m2 IV push or infusion over 2-3 minutes. Day 1
Vinblastine 3 mg/m2 Slow IV push or infusion over Day 1
Doxorubicin 30 mg/m2 Slow IV push or infusion over 15 minutes Day 1
Cisplatin 70 mg/m2 IV infusion over 4 hours Note: May divide dose over two sequential days (35 mg/m2/d x 2 days) if creatinine clearance 50-59 mL/min Day 1* (or divided over Day 1 and Day 2)
Pegfilgrastim 6 mg subcutaneous (SQ) 24-48 hours after completion of chemotherapy.
Followed in 4-8 weeks by radical cystectomy/ureterectomy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically confirmed urothelial carcinoma of bladder, ureter, or renal pelvis. T2-T4 and muscle invasion must be established by TURBT. Upper tract must be high grade. N0-N1 are eligible.
candidate for radical cystectomy, nephroureterectomy, or segmental ureterectomy with goal of cure.
->/= 18 years old
- ECOG performance status 0-1.
- Adequate marrow and organ function.
- May enter on therapeutic anticoagulation if it can be safely held during perioperative period.
- No women of childbearing potential, pregnant or breastfeeding.
- LVEF >/= 50 %
- Patients with history of other non-urothelial malignancies may enroll if: 1)no evidence of distant disease w/in last year. 2)No anticancer treatment for >/= 1 year other than adjuvant treatment or treatment for secondary prevention. 3) Less than 360 mg/m2 lifetime dose of adriamycin.
- ability to understand and willingness to sign written informed consent and HIPAA.
Exclusion Criteria:
- Intravesicular therapy w/in 4 weeks of study entry or those who have not recovered from adverse effects of such agents administered more than 4 weeks earlier.
- Patients may not be receiving any investigational agents within 4 weeks of study entry.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used in the study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy.
Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
-. Patients who have undergone prior pelvic radiation are excluded due to risk of life threatening myelosuppression.
- Patients who have received any previous systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dose dense MVAC
standard doses of MVAC given every 14 days x 3.
|
standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Complete Response at Cystectomy or Ureterectomy Following Preoperative Dose Dense MVAC
Time Frame: Following completion of the 3rd/final cycle of chemotherapy (about week 9) by CT imaging and at time of surgery for pathologic response.
|
complete response rate (pT0), as defined by pathologic staging at cystectomy or ureterectomy, following neoadjuvant DD-MVAC chemotherapy.
|
Following completion of the 3rd/final cycle of chemotherapy (about week 9) by CT imaging and at time of surgery for pathologic response.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity Profile of Dose Dense MVAC Given in the Neoadjuvant Setting.
Time Frame: Ongoing throughout treatment at each MD visit every 14 days.
|
Defined by number of patients who complete all three cycles of treatment without dose reduction
|
Ongoing throughout treatment at each MD visit every 14 days.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elizabeth Plimack, MD, Fox Chase Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Ureteral Diseases
- Kidney Neoplasms
- Carcinoma
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Ureteral Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Doxorubicin
- Liposomal doxorubicin
- Methotrexate
- Vinblastine
Other Study ID Numbers
- FER-GU-026
- NCI-2010-01910 (Registry Identifier: NCI Clinical Trials Reporting Office)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Invasive Bladder Cancer
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
University of VirginiaAmerican Cancer Society, Inc.; Integrated Translational Health Research Institute...RecruitingBladder Cancer | Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
Huazhong University of Science and TechnologyRecruitingBladder Cancer | Non-Muscle-Invasive Bladder CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
White River Junction Veterans Affairs Medical CenterMedical University of South Carolina; National Cancer Institute (NCI); University...RecruitingNon-muscle-invasive Bladder CancerUnited States
-
Al-Azhar UniversityRecruiting
Clinical Trials on single arm dose dense MVAC
-
Pusan National University Yangsan HospitalRecruitingUrothelial Carcinoma | Neoadjuvant Chemotherapy | Muscle Invasive Bladder CancerKorea, Republic of
-
The Cleveland ClinicCompletedOveractive Bladder | Urge Incontinence | Urinary Incontinence, Urge | Overactive Bladder SyndromeUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingNon-Seminomatous Germ Cell TumorFrance
-
Fondazione Italiana Linfomi ONLUSCompletedHodgkin LymphomaItaly
-
Laboratoires TheaCompleted
-
Institut du Cancer de Montpellier - Val d'AurelleFondazione IRCCS ISTITUTO NAZIONALE TUMORIWithdrawnHealthy | Non-small Cell Lung Cancer Stage III | Squamous Cell Carcinoma of Head and Neck | Metastatic Breast Cancer | Metastatic Melanoma | Advanced Renal Cell Carcinoma
-
Martin-Luther-Universität Halle-WittenbergUniversity of Leipzig; Jena University Hospital; St. Elisabeth Hospital HalleCompletedPreterm Premature Rupture of Membranes | Early Onset Neonatal Sepsis | Fetal Inflammatory Response Syndrome | Infection of Amniotic CavityGermany
-
AblynxCompletedHealthy VolunteersUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
PfizerCompleted